19/04/2015 - 20:08 Pembrolizumab was superior to ipilimumab, the standard of care, as first-line therapy for advanced melanoma in the phase III KEYSTONE-006 trial. Pemb... More » Visit websiteField of Interest: OncologyCategories: IMN || NewsIMN || OncologyONCR || NewsONCR || Melanoma & Skin CancersSAN || Clinical NewsSAN || NewsSAN || SCN: MelanomaFPN || NewsNews Feed: Internal Medicine News - Oncology
